E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Retinopathy of prematurity (ROP) |
|
E.1.1.1 | Medical condition in easily understood language |
Retinopathy of prematurity (ROP) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038933 |
E.1.2 | Term | Retinopathy of prematurity |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. • To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. |
|
E.2.2 | Secondary objectives of the trial |
• To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. • To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Key Inclusion Criteria: 1. Patient was treated in study VGFTe-ROP-1920 2. Age <13 months of chronological age 3. Signed informed consent from parent(s)/legal guardian(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol |
|
E.4 | Principal exclusion criteria |
1. Patient has a condition preventing participation in the study, or performance of study procedures |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Binocular best-corrected visual acuity (BCVA) 2. Proportion of Patients with Adverse Events 3. Proportion of Patients with Serious Adverse Events |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1-3. 5 years of chronological age. |
|
E.5.2 | Secondary end point(s) |
1. Proportion of patients developing unfavorable ocular structural outcome 2. BCVA in each eye at 3 and 5 years of chronological age 3. Refractive spherical equivalent in each eye 4. Neurodevelopmental outcomes using Bayley Scales of Infant and Toddler Development (BSID-III) 5. Neurodevelopmental outcomes using echsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) 6. Neurodevelopmental outcomes using Vineland Adaptive Behavior Scales, Second Edition (VABS-II) 7. Proportion of patients with recurrence of ROP 8. Proportion of patients requiring treatment for ROP For full information on secondary end points, see protocol. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1-3, 7. 3 and 5 years of chronological age 4. 2 years of chronological age 5. 5 years of chronological age 6. 2 years of chronological age, 5 years of chronological age 8. Through 5 years of chronological age
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Colombia |
Korea, Republic of |
Russian Federation |
Taiwan |
Thailand |
Turkey |
United States |
Viet Nam |
Bulgaria |
Romania |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
A patient is considered to have completed the study if he/she has completed all phases of the study including the last visit at 5 years of chronological age |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |